BeiGene (NASDAQ:BGNE – Get Rating) had its target price upped by Morgan Stanley from $295.00 to $325.00 in a report published on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock.
BGNE has been the topic of a number of other research reports. Guggenheim raised their target price on BeiGene from $290.00 to $350.00 and gave the company a buy rating in a report on Friday, January 20th. Cowen raised their target price on BeiGene from $200.00 to $213.00 in a report on Thursday, November 10th. StockNews.com upgraded BeiGene from a sell rating to a hold rating in a report on Saturday, November 19th. SVB Leerink raised their target price on BeiGene from $236.00 to $300.00 and gave the company an outperform rating in a report on Friday, January 20th. Finally, Daiwa Capital Markets initiated coverage on BeiGene in a report on Wednesday, January 11th. They set a buy rating and a $308.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, BeiGene currently has an average rating of Moderate Buy and an average price target of $286.43.
BeiGene Trading Down 0.8 %
BGNE opened at $266.75 on Tuesday. BeiGene has a fifty-two week low of $118.18 and a fifty-two week high of $280.62. The firm has a market capitalization of $27.73 billion, a PE ratio of -12.49 and a beta of 0.78. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.07 and a quick ratio of 3.87. The company’s 50-day moving average is $220.10 and its 200 day moving average is $186.90.
Insider Buying and Selling
In other BeiGene news, CEO John Oyler sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $206.84, for a total value of $5,171,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other BeiGene news, insider Xiaodong Wang sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $252.66, for a total value of $631,650.00. Following the completion of the sale, the insider now directly owns 5,512,556 shares of the company’s stock, valued at $1,392,802,398.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Oyler sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $206.84, for a total value of $5,171,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,033 shares of company stock worth $9,407,504. 7.50% of the stock is owned by company insiders.
Institutional Trading of BeiGene
Large investors have recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of BeiGene in the second quarter valued at $6,443,000. KBC Group NV grew its position in shares of BeiGene by 2.3% in the second quarter. KBC Group NV now owns 14,523 shares of the company’s stock valued at $2,351,000 after purchasing an additional 331 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of BeiGene in the second quarter valued at $65,000. Primecap Management Co. CA grew its position in shares of BeiGene by 8.7% in the second quarter. Primecap Management Co. CA now owns 4,031,449 shares of the company’s stock valued at $652,490,000 after purchasing an additional 322,645 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in shares of BeiGene by 13.4% in the third quarter. Teacher Retirement System of Texas now owns 44,368 shares of the company’s stock valued at $5,982,000 after purchasing an additional 5,249 shares in the last quarter. 51.43% of the stock is owned by hedge funds and other institutional investors.
BeiGene Company Profile
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
- Get a free copy of the StockNews.com research report on BeiGene (BGNE)
- Is It Time To Get Aggressive With Defense Stocks?
- When Will Crane Holdings Take Flight?
- 3 Retail Stocks Ringing the Register in 2023
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.